<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dutta D</submitter><funding>Department of Biotechnology, Govt. of India</funding><pagination>81</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11334571</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>31(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded shor</pubmed_abstract><journal>Journal of biomedical science</journal><pubmed_title>EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment.</pubmed_title><pmcid>PMC11334571</pmcid><funding_grant_id>DBT/RA/16/05/2016</funding_grant_id><pubmed_authors>Banerjee S</pubmed_authors><pubmed_authors>Park JH</pubmed_authors><pubmed_authors>Al Hoque A</pubmed_authors><pubmed_authors>Mukherjee B</pubmed_authors><pubmed_authors>Boro P</pubmed_authors><pubmed_authors>Quadir M</pubmed_authors><pubmed_authors>Sepay N</pubmed_authors><pubmed_authors>Dutta D</pubmed_authors><pubmed_authors>Kaipparettu BA</pubmed_authors><pubmed_authors>Laha S</pubmed_authors><pubmed_authors>Chowdhury C</pubmed_authors><pubmed_authors>Paul B</pubmed_authors><pubmed_authors>Choudhury A</pubmed_authors></additional><is_claimable>false</is_claimable><name>EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment.</name><description>&lt;h4>Background&lt;/h4>Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded shor</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2026-06-02T04:47:30.826Z</modification><creation>2025-04-05T12:29:26.184Z</creation></dates><accession>S-EPMC11334571</accession><cross_references><pubmed>39164686</pubmed><doi>10.1186/s12929-024-01069-8</doi></cross_references></HashMap>